Pyridines and derivatives
Apexbio Technology LLC Vadadustat 1000025-07-9 50mg
Vadadustat (CAS 1000025-07-9) is an orally bioavailable inhibitor of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) modulating cellular oxygen-sensing pathways By inhibiting HIF-PH enzymes vadadustat stabilizes hypoxia-inducible factors leading to increased endogenous erythropoietin production and subsequent stimulation of erythropoiesis This mechanism offers an alternative to traditional erythropoiesis-stimulating agents in the management of anemia associated with chronic kidney disease (CKD) especially in patients receiving maintenance dialysis Vadadustat is utilized in biomedical research to explore oxygen-sensing regulation erythropoiesis and novel therapeutic strategies for CKD-related anemia
Apexbio Technology LLC Vadadustat 1000025-07-9 100mg
Vadadustat (CAS 1000025-07-9) is an orally bioavailable inhibitor of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) modulating cellular oxygen-sensing pathways By inhibiting HIF-PH enzymes vadadustat stabilizes hypoxia-inducible factors leading to increased endogenous erythropoietin production and subsequent stimulation of erythropoiesis This mechanism offers an alternative to traditional erythropoiesis-stimulating agents in the management of anemia associated with chronic kidney disease (CKD) especially in patients receiving maintenance dialysis Vadadustat is utilized in biomedical research to explore oxygen-sensing regulation erythropoiesis and novel therapeutic strategies for CKD-related anemia
Apexbio Technology LLC Vadadustat 1000025-07-9 5mg
Vadadustat (CAS 1000025-07-9) is an orally bioavailable inhibitor of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) modulating cellular oxygen-sensing pathways By inhibiting HIF-PH enzymes vadadustat stabilizes hypoxia-inducible factors leading to increased endogenous erythropoietin production and subsequent stimulation of erythropoiesis This mechanism offers an alternative to traditional erythropoiesis-stimulating agents in the management of anemia associated with chronic kidney disease (CKD) especially in patients receiving maintenance dialysis Vadadustat is utilized in biomedical research to explore oxygen-sensing regulation erythropoiesis and novel therapeutic strategies for CKD-related anemia
Medchemexpress LLC (-)-Epipodophyllotoxin | 4375-07-9 | 10 MG
(-)-Epipodophyllotoxin is an antiproliferative agent against cancer cells isolated from American mayapple *Podophyllum peltatum*. It demonstrates GI50s of 0.36 and 0.24 μM in HeLa cells and MCF-7 cells, respectively, and can inhibit mitotic spindle assembly in vitro.
- Purity: 99.95%
- Molecular weight: 414.41
- Formula: C22H22O8
- Appearance: Solid, white to off-white
- Inhibits mitotic spindle assembly in vitro
- Soluble in DMSO (≥ 50 mg/mL)
- For research use only
Apexbio Technology LLC Vadadustat 1000025-07-9 10mg
Vadadustat (CAS 1000025-07-9) is an orally bioavailable inhibitor of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) modulating cellular oxygen-sensing pathways By inhibiting HIF-PH enzymes vadadustat stabilizes hypoxia-inducible factors leading to increased endogenous erythropoietin production and subsequent stimulation of erythropoiesis This mechanism offers an alternative to traditional erythropoiesis-stimulating agents in the management of anemia associated with chronic kidney disease (CKD) especially in patients receiving maintenance dialysis Vadadustat is utilized in biomedical research to explore oxygen-sensing regulation erythropoiesis and novel therapeutic strategies for CKD-related anemia
Medchemexpress LLC (-)-Epipodophyllotoxin | 4375-07-9 | 5 MG
(-)-Epipodophyllotoxin | 4375-07-9 | 5 MG
Medchemexpress LLC Dehydroleucodine | 36150-07-9 | >98.0% | 5MG
Dehydroleucodine | 36150-07-9 | >98.0% | 5MG
Apexbio Technology LLC Sudan I 842-07-9 500mg
Sudan I (842-07-9) is a small-molecule inhibitor targeting microbial growth notably Clostridium perfringens and Clostridium ramosum It is used to modulate bacterial physiology by altering signaling pathways involved in cell viability and replication Sudan I exerts its biological activity primarily through disruption of cellular metabolic processes essential for microbial proliferation In in vitro studies Sudan I demonstrates inhibitory activity with IC50 values typically between 10 30 M depending on the bacterial strain and experimental conditions Based on these pharmacological properties Sudan I holds research potential in microbiology investigation and antimicrobial assay development particularly for studies on microbial inhibition mechanisms and comparative efficacy testing
Apexbio Technology LLC GNF-7 839706-07-9 5mg
GNF-7 (CAS 839706-07-9) is a small molecule type II kinase inhibitor that selectively targets the T315I mutant form of Bcr-Abl a constitutively active tyrosine kinase implicated in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia In vitro GNF-7 exhibits potent growth inhibitory effects in Colo205 SW620 and TrkC-Ba/F3 cell lines with IC50 values of 0 005 0 001 and 0 008 M respectively while displaying minimal activity on normal HEK293T cells In vivo GNF-7 reduces disease burden and improves survival in mouse leukemia models and selectively suppresses NRAS-dependent leukemia cells GNF-7 is valuable for research into kinase inhibitor resistance and targeted leukemia therapies
Medchemexpress LLC Rebastinib | 1020172-07-9 | 99.8% | 100 MG
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive inhibitor targeting Bcr-Abl, including resistant mutants. It effectively inhibits Abl1WT and Abl1T315I, as well as SRC, KDR, FLT3, and Tie-2, with low activity against c-Kit. This compound demonstrates potent antiproliferative effects in various leukemia cell lines and significantly prolongs survival in animal models of leukemia.
- Potently inhibits ABL1 native and ABL1 T315I.
- Inhibits SRC family kinases and PDGFRα/β.
- Selectively spares c-KIT.
- Effectively inhibits proliferation of native BCR-ABL1 and Ph+ K562 cell lines.
- Inhibits proliferation of common TKI-resistant BCR-ABL1 mutants.
- Reduces leukemia cell burden in treated mice.
Medchemexpress LLC Methyclothiazide | 135-07-9 | 99.8% | 5 MG
Methyclothiazide is an orally active antihypertensive and diuretic agent. It reduces the vascular response to endogenous vasoconstricting stimuli and acts against voltage-dependent Ca-channel (VDCC) activity in vitro.
- Orally active antihypertensive agent
- Diuretic agent
- Reduces vascular response to endogenous vasoconstricting stimuli
- Acts against voltage-dependent Ca-channel (VDCC) activity in vitro
- Induces endothelium-dependent inhibition of vasoconstrictor responses
- Shows inhibitory effect on contractile response
- Affects vascular responses to extracellular Ca2+ under high-K⁺ depolarizing conditions
- Reduces Ca2+ contracture
Apexbio Technology LLC GNF-7 839706-07-9 25mg
GNF-7 (CAS 839706-07-9) is a small molecule type II kinase inhibitor that selectively targets the T315I mutant form of Bcr-Abl a constitutively active tyrosine kinase implicated in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia In vitro GNF-7 exhibits potent growth inhibitory effects in Colo205 SW620 and TrkC-Ba/F3 cell lines with IC50 values of 0 005 0 001 and 0 008 M respectively while displaying minimal activity on normal HEK293T cells In vivo GNF-7 reduces disease burden and improves survival in mouse leukemia models and selectively suppresses NRAS-dependent leukemia cells GNF-7 is valuable for research into kinase inhibitor resistance and targeted leukemia therapies
Medchemexpress LLC Lascufloxacin | 848416-07-9 | 98.0% | 439.43 | 1 MG
Lascufloxacin is a potent and orally active fluoroquinolone antibacterial agent. It effectively inhibits infections caused by various pathogens, including quinolone-resistant strains. This product has the potential for treating various infectious diseases, notably lower respiratory tract infections.
- Potent antibacterial activity against quinolone-resistant strains.
- Effective against infections caused by various pathogens.
- Potential for treating lower respiratory tract infections.
- Shows antibacterial activities against *Moraxella catarrhalis* and *Haemophilus influenzae*.
- Inhibits *E. coli* and *P. aeruginosa*.
- Potent activity against macrolide-resistant *M. pneumoniae* isolates.
- Exhibits significant bacterial killing in mouse models of infection.
Medchemexpress LLC Methyclothiazide | 135-07-9 | MFCD00242610 | 99.8% | 1 ML
Methyclothiazide is an orally active antihypertensive and diuretic agent. It functions by reducing the vascular response to endogenous vasoconstricting stimuli such as Norepinephrine. Additionally, Methyclothiazide is active against voltage-dependent Ca-channel (VDCC) in vitro.
- Orally active antihypertensive agent
- Diuretic agent
- Reduces vascular response to vasoconstricting stimuli
- Active against voltage-dependent Ca-channel (VDCC) in vitro
Medchemexpress LLC Lascufloxacin | 848416-07-9 | 98.0% | 439.43 | 5 MG
Lascufloxacin | 848416-07-9 | 98.0% | 439.43 | 5 MG